<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Although <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> induces compensatory increases in beta cell mass and function to maintain normoglycaemia, it is not clear whether <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> can precipitate <z:hpo ids='HP_0006279'>beta cell dysfunction</z:hpo> and <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> without a pre-existing beta cell susceptibility </plain></SENT>
<SENT sid="1" pm="."><plain>We therefore examined the beta <z:mp ids='MP_0005384'>cell phenotype</z:mp> in the MKR mouse, a model in which expression of a dominant-negative IGF 1 receptor (IGF1R) in skeletal muscle leads to systemic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: Circulating <z:chebi fb="105" ids="17234">glucose</z:chebi>, insulin and glucagon concentrations were measured </plain></SENT>
<SENT sid="3" pm="."><plain>Insulin sensitivity, <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance and insulin release in vivo were assessed by i.p. insulin and <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance tests </plain></SENT>
<SENT sid="4" pm="."><plain>Beta cell function was assessed via insulin secretion from isolated islets and the <z:chebi fb="105" ids="17234">glucose</z:chebi> gradient in the perfused pancreas </plain></SENT>
<SENT sid="5" pm="."><plain>Beta cell <z:mp ids='MP_0000002'>morphology</z:mp> was examined via immunohistochemistry </plain></SENT>
<SENT sid="6" pm="."><plain>MKR mice were fed a high-fat diet containing <z:chebi fb="27" ids="17992">sucrose</z:chebi> (HFSD) to test metabolic capacity and beta cell function </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Insulin-resistant MKR mice developed <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and a loss of insulin responsiveness in vivo </plain></SENT>
<SENT sid="8" pm="."><plain>Basal insulin secretion from the perfused pancreas was elevated, with no response to <z:chebi fb="105" ids="17234">glucose</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Despite the demand on insulin secretion, MKR mice had increased pancreatic insulin content and beta cell mass mediated through <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> and <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>The HFSD worsened <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in MKR mice but, despite increased food intake in these mice, failed to induce the <z:hpo ids='HP_0001513'>obesity</z:hpo> observed in <z:mp ids='MP_0002169'>wild-type</z:mp> mice </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS/INTERPRETATION: Our studies demonstrate that <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> of sufficient severity can impair <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion, thereby undermining beta cell compensation and leading to <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Moreover, because insulin stores were intact, the secretory defects reflect an early stage of <z:hpo ids='HP_0006279'>beta cell dysfunction</z:hpo> </plain></SENT>
</text></document>